Date & Time of Session - 9/9/25 - from 12:00 - 1:00PM

Overview: This presentation will provide pharmacists with knowledge about the evolving role of CAR T-cell therapy for non-malignant conditions such as systemic lupus erythematosus, myasthenia gravis and multiple sclerosis. A review of CAR T-cell mechanism, manufacturing process and toxicity monitoring/management is also provided. As more cellular therapies enter the investigational pipeline and are approved, pharmacists will play a critical role in managing patients who may have previously received or are being evaluated to receive CAR T-cell therapy. This foundational presentation on early data of CAR T-cell therapy in non-hematologic conditions equips the pharmacy department to have a baseline understanding of the complexities of these therapies and their implications for clinical practice.

Objectives
Upon completion of this activity, participants will be able to:
1. Recall the mechanism, manufacturing process and key toxicities associated with CAR T-cell therapy.
2. Evaluate emerging data supporting the use of CAR T-cell therapy in non-hematologic diseases.
3. Discuss next steps and the potential role of cellular therapy for autoimmune conditions.

Target Audience
Pharmacists, residents, and students

Special Services
If you require special assistance to attend this event, please call Megan Russel at (304) 550-0896.

Speaker
Ryan Ruehl, PharmD
PGY2 Oncology Pharmacy Resident
UK College of Pharmacy - Lexington, Kentucky